Global regulators must align on new approach methodologies to give sponsors certainty

New approach methodologies, or NAMs, are being promoted as ways to reduce reliance on animal testing in drug development. They promise faster, more humane studies while still providing safety data.

However, sponsors are worried that without consistent acceptance across countries, the benefits of NAMs may be limited. Different regulatory agencies have varied expectations, creating uncertainty for companies planning to use these tools.

Experts say that a coordinated global framework is needed to give sponsors predictability and regulatory assurance. Harmonized guidelines would allow companies to invest in NAMs with confidence that data will be accepted worldwide.

Until such alignment is achieved, the adoption of NAMs may proceed unevenly, potentially slowing the shift toward more ethical and efficient drug testing.